NEW YORK, June 30 - CombiMatrix is collaborating with the Retrovirology Laboratory irsiCaixa, an AIDS research center based in Barcelona, to test the efficacy of its pooled siRNA compounds against Human Immunodeficiency Virus, Type-1, the company said today.
CombiMatrix, an operating division of Acacia Research, said it would work with Bonaventura Clotet, chief of the AIDS unit at the University Hospital Germans Trias i Pujol, to validate its HIV gene-targeted siRNA pools. According to Amit Kumar, president and CEO of CombiMatrix, the company's approach, which targets all of the genes in a virus, "may provide a more powerful therapy than conventional approaches, and it should make it difficult for the virus to develop resistance."
The HIV project is CombiMatrix's second collaboration based on its siRNA platform, following an earlier collaboration based on SARS with the National Institute of Allergy and Infectious Diseases and the US Army Medical Research Institute of Infectious Diseases.
The company said it is targeting a number of other viruses with the siRNA platform, including HIV type 2, West Nile virus, human papillomavirus type 16, human herpes 8 (Kaposi's sarcoma), smallpox (variola), influenza virus A, influenza virus B, hepatitis C, and leishmania RNA virus.